文献速递脑血管病

缺血性卒中后未使用他汀治疗与结局:一项基于人群的研究

Lack of Statin Therapy and Outcomes After Ischemic Stroke: A Population-Based Study.
PubMed 文献 · Stroke · 2023-02-07

该回顾性研究纳入芬兰20家医院收治的59588例缺血性卒中患者,分析出院后90天内未购买他汀处方的患者与不良结局的关系。结果显示27.1%的患者未在出院后90天内使用他汀,未早期使用他汀与1年及12年全因死亡率和主要不良心脑血管事件累积发生率升高相关;随访期间未持续使用他汀与死亡风险升高相关。作者认为需要采取措施改善缺血性卒中后及时使用他汀。

要点

  • 缺血性卒中出院后90天内27.1%的患者未使用他汀,女性及老年患者使用他汀更少。
  • 未早期使用他汀与1年全因死亡率升高相关(7.5% vs 4.4%;HR 1.74 [CI 1.61-1.87])。
  • 未早期使用他汀与1年主要不良心脑血管事件累积发生率升高相关(亚分布HR 1.36 [CI 1.29-1.43])。

核心结论

  • 缺血性卒中后未使用他汀治疗与不良长期结局相关,需要采取措施进一步改善卒中后及时使用他汀。

研究设计与样本

  • 回顾性研究,纳入芬兰20家医院收治的缺血性卒中患者共59588例,数据来自医院收治、死亡、癌症诊断、处方药物购买及特殊报销许可等国家登记库的合并数据。
  • 处方药物使用定义为出院后90天内购买药物,随访期间持续他汀使用按90天间隔分析,中位随访5.7年,采用逆概率治疗加权平衡基线特征、合并症、其他药物及再通治疗差异。

主要发现

  • 27.1%的患者在缺血性卒中出院后90天内未使用他汀治疗,女性和老年患者使用他汀频率较低,12年随访期间平均36.0%的患者未持续使用他汀。
  • 未早期使用他汀的患者1年全因死亡率较高(7.5% vs 4.4%;HR 1.74 [CI 1.61-1.87]),12年全因死亡率较高(56.8% vs 48.6%;HR 1.37 [CI 1.33-1.41])。
  • 未早期使用他汀的患者1年主要不良心脑血管事件累积发生率较高(亚分布HR 1.36 [CI 1.29-1.43]),12年累积发生率较高(亚分布HR 1.21 [CI 1.18-1.25])。
  • 未早期使用他汀的患者心血管死亡、复发性缺血性卒中和心肌梗死更频繁;早期使用他汀与随访期间出血性卒中无关联。
  • 随访期间未持续使用他汀与死亡风险相关(时间依赖分析校正HR 3.03 [CI 2.96-3.23])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statin treatment is effective at preventing adverse vascular events after ischemic stroke (IS). However, many patients fail to use statins after IS. We studied the impact of not using statins after IS on adverse outcomes. METHODS: IS patients (n=59 588) admitted to 20 Finnish hospitals were retrospectively studied. Study data were combined from national registries on hospital admissions, mortality, cancer diagnoses, prescription medication purchases, and permissions for special reimbursements for medications. Usage of prescription medication was defined as drug purchase within 90 days after hospital discharge. Ongoing statin use during follow-up was analyzed in 90-day intervals. Differences in baseline features, comorbidities, other medications, and recanalization therapies were balanced with inverse probability of treatment weighting. Median follow-up was 5.7 years. RESULTS: Statin therapy was not used by 27.1% of patients within 90 days after IS discharge, with women and older patients using statins less frequently. The average proportion of patients without ongoing statin during the 12-year follow-up was 36.0%. Patients without early statins had higher all-cause mortality at 1 year (7.5% versus 4.4% in patients who did use statins; hazard ratio [HR], 1.74 [CI, 1.61-1.87]) and 12 years (56.8% versus 48.6%; HR, 1.37 [CI, 1.33-1.41]). Cumulative incidence of major adverse cerebrovascular or cardiovascular event was higher at 1 year (subdistribution HR, 1.36 [CI, 1.29-1.43]) and 12 years (subdistribution HR, 1.21 [CI, 1.18-1.25]) without early statin use. Cardiovascular death, recurrent IS, and myocardial infarction were more frequent without early statin use. Early statin use was not associated with hemorrhagic stroke during follow-up. Lack of ongoing statin during follow-up was associated with risk of death in time-dependent analysis (adjusted HR, 3.03 [CI, 2.96-3.23]). CONCLUSIONS: Lack of statin treatment after IS is associated with adverse long-term outcomes. Measures to further improve timely statin use after IS are needed.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Åivo J, Ruuskanen JO, Tornio A, et al. Lack of Statin Therapy and Outcomes After Ischemic Stroke: A Population-Based Study. Stroke. 2023. PMID: 36748465. doi:10.1161/STROKEAHA.122.040536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。